Select a community
MS
Find out more about the PatientsLikeMe
MS Community
Home > Community Treatment Reports > Rivastigmine Treatment Report
What is Rivastigmine?

Rivastigmine is a cholinergic agent used for the treatment of mild to moderate dementia of the Alzheimer’s type. Rivastigmine has been available in capsule and liquid formulations since 1997. In 2006, it became the first product approved for Parkinson's disease dementia.

Reasons taken & Efficacy

Reasons and Efficacy
Reasons taken # of patients Major Moderate Slight None Can’t tell # of patients evaluated by
Brain fog 3 0
Memory loss (short term) 2 0
Other 2 0

Mouse over the table for more information

Dosages

  1 PATCH daily 3 mg daily 4.6 mg/24 hr daily 6 mg daily 9.6 mg daily 300 mg daily
  2 Number of Patients: 2 1 Number of Patients: 1 1 Number of Patients: 1 2 Number of Patients: 2 1 Number of Patients: 1 1 Number of Patients: 1  

Duration See details about how long patients take this treatment ▼

Currently Taking Rivastigmine

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
1
1
0
1
1

Adherence, Burden & Cost See details from patient evaluations ▼

Adherence

Taking treatment as prescribed

Always
0 0%
Usually
0 0%
Sometimes
0 0%
Never
0 0%

Burden

Difficulty being on treatment

Very
0 0%
Somewhat
0 0%
A little
0 0%
Not at all
0 0%

Cost

Paid out of pocket

$200+
0 0%
$100-199
0 0%
$50-99
0 0%
$25-49
0 0%
< $25
0 0%

See more information, including instructions, precautions, side effects, and interactions.

Report created on November 22, 2009.